Evidence map›Paper›PMID 39076731›Full record

ReviewReviews in cardiovascular medicine2023

Update on Percutaneous Treatment for HFrEF: A Great Armamentarium for a Poor Ventricular Function.

Antonio Sisinni, Matteo Casenghi, Antonio Popolo Rubbio, Andrea Berni, Francesco Bedogni, Emanuele Barbato

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonio SisinniClinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy.
Matteo CasenghiDepartment of Clinical and Molecular Medicine, School of Medicine and Psychology, University of Rome "La Sapienza", 1035 Rome, Italy.
Antonio Popolo RubbioClinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy.
Andrea BerniDepartment of Clinical and Molecular Medicine, School of Medicine and Psychology, University of Rome "La Sapienza", 1035 Rome, Italy.
Francesco BedogniClinical and Interventional Cardiology Department, IRCCS Policlinico San Donato, 20097 San Donato Milanese, Italy.
Emanuele BarbatoDepartment of Clinical and Molecular Medicine, School of Medicine and Psychology, University of Rome "La Sapienza", 1035 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacological treatment is the cornerstone therapy of heart failure with reduced ejection fraction (HFrEF). In addition, several percutaneous techniques have been developed to treat symptomatic patients, with specific heart failure (HF) phenotypes (e.g., valvular heart disease) that require non-pharmacological treatment. Given their prognostic relevance, it is imperative to deliver high-level patient care. This review provides a clinical overview on the available data regarding transcatheter devices in the armamentarium of contemporary interventional cardiologists, focusing on the clinical and anatomical selection criteria.

Indexed as

emerging technologyheart failure with reduced ejection fractionmedical therapypercutaneous treatmenttranscatheter device

Identifiers

PMID39076731
PMCPMC11273015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.